Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2NSCLC 1Meningeal Carcinomatosis 1Carcinoma 1Brain Neoplasms 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Saline Solution 5Sugammadex 2Sodium Chloride 2Sevoflurane 2Propofol 2Magnetic Resonance Spectroscopy 2Levetiracetam 2Fluorescein 2Dexmedetomidine 2Anesthesia, Inhalation 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1perampanel 1pegvisomant 1lorlatinib 1gadoterate meglumine 1gadobenic acid 1dexketoprofen trometamol 1clevidipine 1Trastuzumab 1Tramadol 1Temozolomide 1Positron-Emission Tomography 1Phenylephrine 1Patient-Specific Modeling 1PF-05280014 1PAVE protocol 2 1Ontruzant 1Ogivri 1Octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Brain Neoplasms × lorlatinib × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡